Get started
Author

Enrico Sammarco

Observed names: ENRICO SAMMARCO, Enrico SAMMARCO, SAMMARCO, ENRICO
ORCID: 0000-0002-1390-918X
Observed ORCID: 0000-0002-1390-918X
OpenAlex ID: A5073855641
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 61
Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
2023 · Enrico Sammarco, Fiorella Manfredi, et al. · Cancers · 21
PDF
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone
2020 · Stefania Crucitta, Marzia Del Re, et al. · Cancer Chemotherapy and Pharmacology · 13
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial
2022 · Andrea Antonuzzo, Carla Ida Ripamonti, et al. · Frontiers in Oncology · 12
PDF
Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm
2024 · Federico Paolieri, Enrico Sammarco, et al. · Clinical Genitourinary Cancer · 10
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting
2025 · Matteo Bauckneht, Laura Evangelista, et al. · Clinical and Translational Imaging · 8
PDF
Proposal for a New Diagnostic Histopathological Approach in the Evaluation of Ki-67 in GEP-NETs
2022 · Pinuccia Faviana, Laura Boldrini, et al. · Diagnostics · 7
PDF
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
2025 · Philipp Mandel, Daniel Groener, et al. · European Journal of Cancer · 5
First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm
2024 · Francesco Bloise, Fiorella Manfredi, et al. · Cells · 5
PDF
Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma
2024 · Enrico Sammarco, Martina Rossetti, et al. · Medical Oncology · 5
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
2025 · Ondrej Fiala, Francesco Grillone, et al. · European Urology Open Science · 4
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings
2026 · Matteo Bauckneht, Laura Evangelista, et al. · Clinical and Translational Imaging · 3
PDF
Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective Analysis
2022 · Amedeo Nuzzo, Simona Manacorda, et al. · Vaccines · 3
PDF
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine
2026 · Chiara Mercinelli, Fabrizio Di Costanzo, et al. · Expert Review of Anticancer Therapy · 2
Steroid Hormones as Modulators of Emotional Regulation in Male Urogenital Cancers
2022 · Pinuccia Faviana, Laura Boldrini, et al. · International Journal of Behavioral Medicine · 2
PDF
New diagnostic histopathological approach in the evaluation of Ki-67 in GEP-NETs
2022 · Pinuccia Faviana, Laura Boldrini, et al. · Research Square · 2
Dedifferentiated Liposarcoma: When Eribulin can make the Difference
2019 · Andrea Sbrana, Federico Paolieri, et al. · Future Oncology · 2
Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma
2026 · Enrico Sammarco, Antonio Pellino, et al. · Cancers · 1
PDF
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival
2026 · Luigi Coltelli, Paola Orlandi, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 1
PDF
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
2025 · Renate Pichler, Gerald Klinglmair, et al. · Clinical & Experimental Metastasis · 1
NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies—a narrative review
2026 · Andrea Marini, Irene Stasi, et al. · Translational Lung Cancer Research
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study
2026 · Pasquale RESCIGNO, Tarek TAHA, et al. · Minerva Urology and Nephrology
Early Versus Late Postoperative Radiotherapy in Patients With Prostate Cancer: Results of a Single-centre Retrospective Study
2022 · FRANCESCO PASQUALETTI, ELISA CALISTRI, et al. · Anticancer Research
New diagnostic histopathological approach in the evaluation of Ki-67 in GEP-NETs
2022 · Pinuccia Faviana, Laura Boldrini, et al. · Research Square
PDF
Works count: 25
Citation count: 168
H-index: 7
I10-index: 5
Year
Topic
Type